AVBP
ArriVent BioPharma Inc.

121
Mkt Cap
$909.43M
Volume
94.00
52W High
$29.57
52W Low
$15.47
PE Ratio
-5.20
AVBP Fundamentals
Price
$22.03
Prev Close
$22.64
Open
$21.65
50D MA
$22.28
Beta
0.91
Avg. Volume
417,604.60
EPS (Annual)
-$2.39
P/B
2.95
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5.8% - Here's What Happened
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 5.8% - Should You Sell...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 8.2% - What's Next?
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 8.2% - What's Next...
MarketBeat·16d ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 7.4% - Here's What Happened
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 7.4% - Time to Sell...
MarketBeat·1mo ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2% - What's Next?
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2% - Time to Sell...
MarketBeat·1mo ago
News Placeholder
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat.com...
MarketBeat·2mo ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6% - Here's What Happened
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 5.6% - Time to Sell...
MarketBeat·2mo ago
News Placeholder
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B PR Newswire VANCOUVER, BC, Dec. 16, 2025 Issued on...
PR Newswire·2mo ago
News Placeholder
Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP
Fund 1 Investments LLC bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·2mo ago
News Placeholder
BTIG Research Upgrades ArriVent BioPharma (NASDAQ:AVBP) to "Strong-Buy"
BTIG Research upgraded shares of ArriVent BioPharma to a "strong-buy" rating in a report on Wednesday...
MarketBeat·2mo ago
News Placeholder
What is Lifesci Capital's Estimate for AVBP FY2025 Earnings?
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Investment analysts at Lifesci Capital cut their FY2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research note issued on...
MarketBeat·3mo ago
<
1
2
...
>

Latest AVBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.